Last reviewed · How we verify
NCT05610592
Tumor Budding in Patients With Colorectal Cancer Under Different MMR Status
trial testing total mesorectal exicision in Tumor Budding in 480 participants. Completed in 1 November 2022.
1 November 2022
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 480 |
| Start date | 1 January 2009 |
| Primary completion | 1 November 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- total mesorectal exicision
Conditions studied
- Tumor Budding — all drugs for Tumor Budding →
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 80, any sex, with Tumor Budding or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the ability of tumor budding to identify prognosis in different MMR states and different levels of tumor lymphocyte infiltration. Tumor budding is usually defined as an isolated single cancer cell or a cluster of up to four cancer cells located at the front of an infiltrating tumor.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.
Nikolouzakis TK, Chrysos E, Docea AO, Fragkiadaki P, et al · · 2024 · cited 20× · PMID 38893120 · DOI 10.3390/cancers16111995 -
Effects of tumour budding on adjuvant chemotherapy in colorectal cancer.
Xie H, Zeng Z, Hou Y, Ye F, et al · · 2024 · cited 3× · PMID 38190579 · DOI 10.1093/bjsopen/zrad115
Verify or expand the search:
- PubMed search for NCT05610592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05610592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 9 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05610592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing